![]() |
市場調查報告書
商品編碼
2086005
輸尿管鏡市場:2026-2032年全球市場預測(依產品類型、應用、技術、應用領域及最終用戶分類)Ureteroscope Market by Product Type, Usage, Technology, Application, End User - Global Forecast 2026-2032 |
||||||
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計到 2032 年,輸尿管鏡市場規模將成長至 19.1 億美元,複合年成長率為 9.16%。
| 主要市場統計數據 | |
|---|---|
| 基準年 2025 | 10.3億美元 |
| 預計年份:2026年 | 11.2億美元 |
| 預測年份 2032 | 19.1億美元 |
| 複合年成長率 (%) | 9.16% |
輸尿管鏡市場的發展受到全球尿道結石負擔日益加重、內視鏡泌尿系統計畫不斷擴展以及對微創泌尿系統治療需求持續成長的驅動。腎結石是最常見的泌尿系統疾病之一,根據美國國家腎臟基金會統計,超過十分之一的美國人在一生中的某個階段會患上腎結石。同行評審的流行病學研究也表明,腎結石的發生率持續上升,且與肥胖、糖尿病、脫水、飲食習慣和氣候變暖等因素密切相關。
輸尿管鏡檢查,包括軟式、半硬式、可重複使用和一次性等類型,在輸尿管結石和腎結石的診斷和治療中發揮核心作用。美國泌尿系統協會 (AUA) 和歐洲泌尿系統協會 (EAU) 的指南均認可輸尿管鏡檢查是許多輸尿管結石和腎結石的首選治療方案,並推薦採用,尤其是在雷射碎石術、數位成像技術和小直徑內鏡等技術的進步顯著提高了手術精度、結石處理和患者康復方面。
輸尿管鏡市場格局正從傳統的可重複使用系統轉向更均衡的生態系統轉變,該生態系統涵蓋數位軟性輸尿管鏡、一次性輸尿管鏡、高清成像和整合雷射功能。可重複使用的輸尿管鏡需要維修、消毒、追蹤和停機管理,而拋棄式輸尿管鏡則具有性能可預測性,並減少了再處理負擔,這促使醫院重新評估總體擁有成本 (TCO)。
人工智慧(AI)並非取代醫師的決策,而是在整個輸尿管鏡檢查流程中創造累積價值。在術前規劃階段,AI驅動的影像分析可以利用CT和超音波資料輔助進行結石檢測、體積估算和風險分層。在手術過程中,電腦視覺技術的進步實現了結石的自動識別、解剖方位辨識、影像增強和記錄,有助於減輕複雜輸尿管鏡檢查病例的認知負荷。
亞太地區是輸尿管鏡技術應用最活躍的地區之一,這得益於中國和印度龐大的患者群體、日本、韓國和澳洲先進的泌尿系統內視鏡醫療體系,以及東南亞地區私立醫院投資的不斷成長。高人口密度、都市區飲食、糖尿病盛行率以及液體攝取模式的多樣性,都促使人們對體外震波碎石術的認知不斷提高,手術量也隨之增加,因此,在全部區域普及軟性輸尿管鏡、雷射碎石術以及經濟實惠的醫療設備至關重要。
隨著印尼、泰國、越南、馬來西亞和菲律賓不斷擴大醫院基礎設施、專科培訓和醫療旅遊體系,東協的重要性日益凸顯,對經濟高效的輸尿管鏡平台、永續的服務模式和實用的臨床教育的需求也隨之成長。在海灣合作理事會(GCC)國家,高溫、脫水風險以及與代謝性疾病相關的高發生性泌尿系結石,使得臨床需求特別迫切。沙烏地阿拉伯、阿拉伯聯合大公國、卡達和科威特的高階醫院越來越傾向於採用先進的數位輸尿管鏡、一次性系統和雷射平台,以支持高效的結石治療。
美國在手術量、創新技術應用、雷射碎石術和門診輸尿管鏡檢查方面均處於主導。同時,加拿大透過公共資助的醫院系統穩步推進相關技術的應用,該系統注重治療效果、安全性和成本控制。墨西哥和巴西是拉丁美洲的重要市場,當地的私人醫院和公立三級醫療機構正在擴大軟性輸尿管鏡檢查和微創結石治療的覆蓋範圍。英國、德國、法國、義大利和西班牙擁有先進的泌尿外科網路,其中德國在醫療技術評估、手術標準化和醫院採購系統方面尤為突出。而法國和英國則更注重以指引為基礎的診療路徑、泌尿系統控制以及醫療系統的效率。
行業領導者需要產品系列與實際臨床和營運需求保持一致。這包括提供可重複使用和一次性輸尿管鏡選項、改進服務模式、確保維修成本透明、支援消毒流程,以及確保與钬和铥光纖雷射系統相容。供應商應投資於醫生培訓、模擬和指導,因為臨床環境中的信心直接影響產品的採用、使用和重複購買。
本調查方法基於二手資料研究、專家檢驗以及運用三角測量法整合市場資訊。二手資訊來源包括美國泌尿系統協會 (AUA) 和歐洲泌尿系統協會 (EAU) 的泌尿系統指南、美國食品藥品監督管理局 (FDA) 和歐洲監管機構的監管資料庫、醫院採購模式、同行評審的流行病學研究、醫療設備安全資訊、報銷標準參考資料、臨床文獻以及醫療技術製造商提供的公開資訊。
隨著泌尿系統結石患者數量的持續成長,以及醫療系統對微創、高效且符合指南的泌尿系統治療的日益重視,輸尿管鏡市場預計將保持其重要性。軟性數位成像、雷射碎石術、一次性輸尿管鏡、改進的消毒方法以及人工智慧驅動的工作流程工具等技術進步正在重塑臨床實踐和採購決策。
The Ureteroscope Market is projected to grow by USD 1.91 billion at a CAGR of 9.16% by 2032.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2025] | USD 1.03 billion |
| Estimated Year [2026] | USD 1.12 billion |
| Forecast Year [2032] | USD 1.91 billion |
| CAGR (%) | 9.16% |
The ureteroscope market is anchored by the growing global burden of urinary stone disease, expanding endourology programs, and sustained demand for minimally invasive urological care. Kidney stones are among the most common urologic disorders, with the National Kidney Foundation citing that more than one in ten people in the United States will develop a kidney stone during their lifetime, while peer-reviewed epidemiology consistently shows rising incidence linked to obesity, diabetes, dehydration, diet, and warmer climates.
Ureteroscopes, including flexible, semi-rigid, reusable, and single-use platforms, are central to ureteroscopy for diagnosing and treating ureteral and renal stones. Adoption is supported by American Urological Association and European Association of Urology guidance that recognizes ureteroscopy as a key treatment option for many ureteral and intrarenal stones, particularly as laser lithotripsy, digital imaging, and smaller scope diameters improve procedural precision, stone management, and patient recovery.
The ureteroscope landscape is shifting from conventional reusable systems toward a more balanced ecosystem that includes digital flexible ureteroscopes, disposable ureteroscopes, high-definition visualization, and integrated laser compatibility. Hospitals are reassessing total cost of ownership as reusable scopes require repair, sterilization, tracking, and downtime management, while single-use devices offer predictable performance and reduced reprocessing burden.
Clinical practice is also moving toward outpatient and ambulatory surgical settings as anesthesia protocols, miniaturized instruments, and same-day discharge pathways mature. These shifts are reinforced by infection-control expectations, central sterile processing constraints, and growing pressure to improve operating room efficiency without compromising safety, visualization quality, or stone-free outcomes.
Artificial intelligence is creating cumulative value across the ureteroscope workflow rather than replacing physician decision-making. In preoperative planning, AI-supported imaging analytics can assist stone detection, volume estimation, and risk stratification using CT and ultrasound data. During procedures, computer vision research is advancing stone recognition, anatomical orientation, image enhancement, and automated documentation, helping reduce cognitive load in complex ureteroscopy cases.
Operationally, AI can strengthen case scheduling, scope utilization forecasting, repair prediction, and inventory planning for reusable and single-use ureteroscope fleets. The strongest near-term impact is expected in decision support, quality analytics, and procedural standardization, provided systems remain clinically validated, compliant with medical device regulations, and transparent for urologists, hospital administrators, and procurement teams.
Asia-Pacific represents one of the most dynamic environments for ureteroscope adoption, supported by large patient pools in China and India, advanced endourology capacity in Japan, South Korea, and Australia, and increasing private hospital investment across Southeast Asia. High population density, urban diets, diabetes prevalence, and uneven hydration patterns are contributing to higher stone disease recognition and procedure volumes, making flexible ureteroscopy, laser lithotripsy, and cost-effective device access important priorities across the region.
North America remains a high-value environment due to established urology networks, guideline-driven care, advanced laser adoption, ambulatory surgical capabilities, and strong reimbursement infrastructure. Europe benefits from mature endoscopic surgery standards and European Union medical device regulation that emphasizes clinical evidence, safety, post-market surveillance, and traceability. Latin America is expanding through Brazil and Mexico as tertiary centers and private hospitals invest in flexible ureteroscopy, while the Middle East shows elevated relevance because several countries sit within the global stone belt, where hot climates and dehydration risk increase clinical need. Africa remains earlier in adoption, with demand concentrated in urban referral hospitals and constrained by equipment availability, trained specialists, financing, and sterilization capacity.
ASEAN is becoming increasingly important as Indonesia, Thailand, Vietnam, Malaysia, and the Philippines expand hospital infrastructure, specialist training, and medical tourism capabilities, creating demand for cost-effective ureteroscope platforms, durable service models, and practical clinical education. The GCC has a strong clinical need due to high stone prevalence associated with hot climates, dehydration risk, and metabolic disease; premium hospitals in Saudi Arabia, the United Arab Emirates, Qatar, and Kuwait are receptive to advanced digital ureteroscopes, single-use systems, and laser-compatible platforms that support efficient stone management.
The European Union emphasizes compliance with the EU Medical Device Regulation, sustainability, procurement transparency, and evidence-based adoption, making durability, lifecycle cost, clinical validation, and post-market performance central to vendor success. BRICS countries combine large untreated demand with expanding domestic manufacturing, hospital modernization, and public healthcare investment, while the G7 remains a hub for premium innovation, clinical research, guideline-aligned practice, and early adoption of digital endourology. NATO markets overlap significantly with high-income procurement systems where supply resilience, cybersecurity, device traceability, sterile processing reliability, and continuity of care influence purchasing decisions.
The United States leads in procedure volume, innovation adoption, laser lithotripsy use, and ambulatory ureteroscopy, while Canada shows steady uptake through publicly funded hospital systems focused on outcomes, safety, and cost control. Mexico and Brazil are important Latin American markets where private hospitals and tertiary public centers are expanding access to flexible ureteroscopy and minimally invasive stone treatment. The United Kingdom, Germany, France, Italy, and Spain maintain sophisticated urology networks, with Germany particularly strong in medical technology evaluation, procedural standardization, and hospital procurement discipline, while France and the United Kingdom emphasize guideline-aligned care pathways, infection control, and health system efficiency.
Russia retains demand across major urban centers despite procurement and import constraints, with access shaped by regional hospital budgets and specialist availability. China and India are among the most consequential growth markets because of scale, rising diagnosis, urbanization, diabetes burden, and hospital modernization. Japan and South Korea prioritize high-quality visualization, precision instruments, compact device design, and advanced endourology training, while Australia benefits from strong specialist networks, modern hospital infrastructure, and adoption of minimally invasive stone management across metropolitan and referral hospitals.
Industry leaders should align product portfolios with real-world clinical and operational needs. This includes offering both reusable and single-use ureteroscope options, strengthening service models, providing transparent repair economics, supporting sterilization workflows, and ensuring compatibility with holmium and thulium fiber laser systems. Vendors should invest in physician training, simulation, and proctoring because clinical confidence directly affects adoption, utilization, and repeat purchasing.
Manufacturers and distributors should also prioritize evidence generation, infection-control documentation, device durability data, and lifecycle cost studies for hospital procurement teams. In growth markets, modular pricing, local service capacity, distributor quality, and partnerships with urology societies can accelerate access. For AI-enabled features, companies should pursue clinically validated, regulator-ready tools that improve workflow, image quality, stone recognition, and documentation without overclaiming autonomous capability.
The research methodology integrates secondary research, expert validation, and triangulated market intelligence. Secondary inputs include urology guidelines from the American Urological Association and European Association of Urology, regulatory databases from authorities such as the U.S. FDA and European regulators, hospital procurement patterns, peer-reviewed epidemiology, device safety information, reimbursement references, clinical literature, and public disclosures from medical technology manufacturers.
Primary validation typically includes interviews with urologists, endourology specialists, procurement managers, distributors, biomedical engineers, and sterile processing stakeholders. Findings are triangulated across procedure trends, installed base indicators, regulatory approvals, reimbursement context, clinical adoption patterns, and competitive product positioning. This approach supports data-backed insight while avoiding unsupported claims and ensuring that interpretation reflects clinical, operational, regulatory, and regional realities.
The ureteroscope market is positioned for sustained relevance as stone disease continues to rise and healthcare systems prioritize minimally invasive, efficient, and guideline-supported urological care. Technology advances in flexible digital imaging, laser lithotripsy, single-use ureteroscopes, improved sterilization practices, and AI-enabled workflow tools are reshaping clinical practice and procurement decisions.
Success will depend on balancing performance, safety, economics, and access. Organizations that provide validated technology, strong service support, region-specific pricing, reliable training, and credible clinical education will be best positioned to meet demand across mature markets and emerging healthcare systems.